1.
Girish C,
Vijayalakshmi P,
Mentham R,
Rao CB.
A REVIEW ON BREAST CANCER.
Int J Pharm Bio Sc.
2014;4(2):47–54.
2.
Soto-Perez-de-Celis E,
Chavarri-Guerra Y.
National and regional breast cancer incidence and mortality trends in Mexico 2001–2011: Analysis of a population-based database.
Cancer Epidemiology.
Elsevier Ltd; 2016 Apr 1;41:24–33.
3.
Archivo clínico Centro Médico ABC.
4.
Youlden DR,
Cramb SM,
Dunn NAM,
Muller JM,
Pyke CM,
Baade PD.
The descriptive epidemiology of female breast cancer: An international comparison of screening,
incidence,
survival and mortality.
Cancer Epidemiology.
Elsevier Ltd; 2012 Jun 1;36(3):237–48.
5.Ban KA,
Godellas CV.
Epidemiology of breast cancer.
Surg Oncol Clin N Am.
2014 Jul;23(3):409–22.
6.
Rozenberg S,
Carly B,
Liebens F,
Antoine C.
Risks of osteoporosis associated with breast cancer treatment: The need to access to preventive treatment.
Maturitas.
2009 Sep;64(1):1–3.
7.
Obi N,
Gornyk D,
Heinz J,
Vrieling A,
Seibold P,
Chang-Claude J,
et al.
Determinants of newly diagnosed comorbidities among breast cancer survivors.
J Cancer Surviv.
2014 Feb 26;8(3):384–93.
8.
Nagaraja AS,
Sadaoui NC,
Lutgendorf SK,
Ramondetta LM,
Sood AK.
β-blockers: a new role in cancer chemotherapy.
Expert Opin Investig Drugs.
2013 Nov;22(11):1359–63.
9.
Cole SW,
Sood AK.
Molecular Pathways: Beta-Adrenergic Signaling in Cancer.
Clinical Cancer Research.
2012 Mar 1;18(5):1201–6.
10.
Becker C.
Pathophysiology and Clinical Manifestations of Osteoporosis.
Clinical Cornerstone.
Excerpta Medica; 2008;9(2):42–50.
11.
Kasturi GC,
Cifu DX,
Adler RA.
A review of osteoporosis: part I.
Impact,
pathophysiology,
diagnosis and unique role of the physiatrist.
PM R.
Elsevier; 2009 Mar;1(3):254–60.
12.
De Tejada Romero MJG,
Henríquez MS.
Osteoporosis: definición,
tendencia epidemiológica,
avances en la fisiopatología y clínica.
Medicine.
Elsevier; 2014 Jun 1;11(60):3527–34.
13.
Lentle BC,
Prior JC.
Osteoporosis: What a Clinician Expects to Learn from a Patient’s Bone Density Examination1.
Radiology.
2003 Sep;228(3):620–8.
14.
Rachner TD,
Khosla S,
Hofbauer LC.
New horizons in osteoporosis.
Lancet.
2011;377(9773):1276–87.
15.
Clark P.
Osteoporosis in Mexico:“ the challenge.” Salud Pública de México.
2009;51:s2–s3.
16.
Rossini M,
Adami S,
Bertoldo F,
Diacinti D,
Gatti D,
Giannini S,
et al.
Guidelines for the diagnosis,
prevention and management of osteoporosis.
Reumatismo.
2016;68(1):1–39.
17.
Guglielmi G,
Muscarella S,
Bazzocchi A.
Integrated Imaging Approach to Osteoporosis: State-of-the-Art Review and Update.
RadioGraphics.
2011 Sep;31(5):1343–64.
18.
Kanis JA,
Seeman E,
Johnell O,
Rizzoli R,
Delmas P.
The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry.
Osteoporos Int.
2005 Feb 24;16(5):456–9.
19.
Patel AA,
Ramanathan R,
Kuban J,
Willis MH.
Imaging Findings and Evaluation of Metabolic Bone Disease.
Advances in Radiology.
2015;2015(3):1–21.
20.
Blake GM,
Fogelman I.
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.
Postgraduate Medical Journal.
2007 Aug 1;83(982):509–17.
21.
Adams JE.
Quantitative computed tomography.
European Journal of Radiology.
2009 Sep;71(3):415–24.
22.
Pickhardt PJ,
Pooler BD,
Lauder T,
del Rio AM,
Bruce RJ,
Binkley N.
Opportunistic Screening for Osteoporosis Using Abdominal Computed Tomography Scans Obtained for Other Indications.
Ann Intern Med.
2013 Apr 16;158(8):588–22.
23.
Batawil N,
Sabiq S.
Hounsfield unit for the diagnosis of bone mineral density disease: A proof of concept study.
Radiography.
Elsevier Ltd; 2016 May 1;22(2):e93–8.
24.
MD CCJ,
MD EBG,
MD AJW,
MD JML,
MD JJS.
Using Hounsfield Units to Assess Osteoporotic Status on Wrist Computed Tomography Scans: Comparison With Dual Energy X-Ray Absorptiometry.
Journal of Hand Surgery.
Elsevier Inc; 2016 May 13;:1–8.
25.
Radiology ACO.
ACR–SPR–SSR Practice Parameter for the Performance of Quantitative Computed Tomography (QCT) Bone DensitometryACR–SPR–SSR Practice Parameter for the Performance of Quantitative Computed Tomography (QCT) Bone Densitometry.
American college of radiology.
2014 Jul pp.
1–14.
26.
Trémollieres FA.
Screening for osteoporosis after breast cancer: For whom,
why and when.
Maturitas.
Elsevier Ireland Ltd; 2014 Nov 1;79(3):343–8.
27.
Nishino M,
Jagannathan JP,
Ramaiya NH,
Van den Abbeele AD.
Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know.
American Journal of Roentgenology.
2010 Aug;195(2):281–9.
28.
Floriano-Sanchez E,
Rodriguez NC,
Bandala C,
Coballase-Urrutia E,
Lopez-Cruz J.
CYP3A4 Expression in Breast Cancer and its Association with Risk Factors in Mexican Women.
Asian Pacific Journal of Cancer Prevention.
2014 Apr 30;15(8):3805–9.
29.
Parada-Huerta E,
Alvarez-Dominguez T,
Uribe-Escamilla R,
Rodriguez-Joya J,
Ponce-Medrano JD,
Padron-Lucio S,
et al.
Metastasis Risk Reduction Related with Beta-Blocker Treatment in Mexican Women with Breast Cancer.
Asian Pacific Journal of Cancer Prevention.
2016;17(6):2953–7.
30.
Leon-Hernandez SR,
Padilla EL,
Algara AC,
Rodriguez NC,
Sanchez EF,
Cruz JL,
et al.
Relation of Alcohol/Tobacco use with Metastasis,
Hormonal (Estrogen and Progesterone) Receptor Status and c-erbB2 Protein in Mammary Ductal Carcinoma.
Asian Pacific Journal of Cancer Prevention.
2014 Jul 30;15(14):5709–14.
31.
Bandala C,
Floriano-Sanchez E,
Cardenas-Rodriguez N,
Lopez-Cruz J,
Lara-Padilla E.
RNA Expression of Cytochrome P450 in Mexican Women with Breast Cancer.
Asian Pacific Journal of Cancer Prevention.
2012 Jun 30;13(6):2647–53.
32.
Lara-Medina F,
Pérez-Sánchez V,
Saavedra-Pérez D,
Blake-Cerda M,
Arce C,
Motola-Kuba D,
et al.
Triple-negative breast cancer in Hispanic patients.
Cancer.
2011 Mar 8;117(16):3658–69.
33.
Cardenas-Rodriguez N,
Lara-Padilla E,
Bandala C,
Lopez-Cruz J,
Uscanga-Carmona C,
Lucio-Monter PF,
et al.
CYP2W1,
CYP4F11 and CYP8A1 Polymorphisms and Interaction of CYP2W1 Genotypes with Risk Factors in Mexican Women with Breast Cancer.
Asian Pacific Journal of Cancer Prevention.
2012 Mar 31;13(3):837–46.